Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NST-628 |
Synonyms | |
Therapy Description |
NST-628 stabilizes the RAF-MEK complex, which inhibits MEK/ERK/RSK phosphorylation and reactivation of the pathway, potentially leading to tumor growth inhibition (Mol Cancer Ther (2023) 22 (12_Supplement): A086, Mol Cancer Ther (2023) 22 (12_Supplement): A088). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NST-628 | NST628|NST 628 | NST-628 stabilizes the RAF-MEK complex, which inhibits MEK/ERK/RSK phosphorylation and reactivation of the pathway, potentially leading to tumor growth inhibition (Mol Cancer Ther (2023) 22 (12_Supplement): A086, Mol Cancer Ther (2023) 22 (12_Supplement): A088). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | melanoma | predicted - sensitive | NST-628 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NST-628 induced tumor regression in a melanoma cell line xenograft model harboring NRAS Q61L (Mol Cancer Ther (2023) 22 (12_Supplement): A088). | detail... |
NRAS Q61R | melanoma | predicted - sensitive | NST-628 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NST-628 treatment resulted in tumor regression in an intracranial melanoma cell line xenograft model harboring NRAS Q61R (Mol Cancer Ther (2023) 22 (12_Supplement): A089). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06326411 | Phase I | NST-628 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628) | Recruiting | AUS | 0 |